Lineage Cell TherapeuticsLCTX
Recorded

Lineage Cell Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 8 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Lineage Cell Therapeutics Third Quarter 2026 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I will now introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.

Ioana HoneHead of Investor Relations

Thank you, Audra. Good afternoon, and thank you for joining us. A press release reporting our third quarter 2026 financial results was issued earlier today, November 12, 2026, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements.

Ioana HoneHead of Investor Relations

For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statement sections in today's press release and in the company's SEC filings, including its most recent annual report on Form 10-K and in the Form 10-Q filed today. We caution you not to place undue reliance on any forward-looking statements, which speak only as of today and are qualified by the cautionary statements and risk factors described in our SEC filings. With us today are Brian Culley, our Chief Executive Officer, Jill Howe, our Chief Financial Officer, and Dr. Priyantha Herath, our Senior Vice President and Head of Clinical. I'll now hand the call over to Brian.

Brian CulleyCEO

Thank you, Ioana. Good afternoon, everyone, to what I expect will be an important and memorable earnings call. Just a few minutes ago, we announced that we had acquired NeuroAirmid Therapeutics, a private biotech company founded on technology licensed from the lab of world-leading Huntington's disease researcher, Dr. Leslie Thompson. NeuroAirmid holds certain rights to HUNT1, formerly known as hNSC01, which is a clinical-stage neural stem cell program currently enrolling patients in a phase I-B/II-A clinical trial for the treatment of Huntington's disease, a fatal neurodegenerative disorder. With this transformational deal, we have secured an entirely new clinical-stage cell therapy program, which immediately becomes a key part of Lineage's clinical portfolio.

Brian CulleyCEO

I plan to spend most of today's call outlining in detail why we are so excited about this acquisition and how we believe the addition of a third clinical-stage asset to our pipeline, alongside OpRegen and OPC1, will enhance our business and drive future value. Before I dive into this breaking news, I want to provide some short updates on our other programs. I will start with OpRegen, which of course remains tremendously important as our lead program. OpRegen continues to be evaluated by Genentech in a Phase IIa study named GAlette in patients with geographic atrophy secondary to age-related macular degeneration. GAlette is intended to optimize surgical delivery to the subretinal space and evaluate the safety and efficacy in OpRegen in patients with GA.

Brian CulleyCEO

As you're all aware, we are not able to provide guidance on our partner's timing for further clinical development, but we remain confident that the OpRegen program is being well-supported within the Roche and Genentech organizations. Some of you have asked me recently about public records found on an FDA website, and that disclose information about several hundred vials of OpRegen drug product labeled for clinical trial use that has recently been shipped to Genentech from our GMP manufacturing facility. Under the terms of our agreement with Roche and Genentech, I cannot comment on anything outside of publicly available facts. Today, I can only affirm that the information regarding the production, release, and shipment of clinical material from multiple batches of OpRegen is accurate.

Brian CulleyCEO

The other note I will share today about OpRegen is to call out some activity in the RPE transplant competitive landscape, which we observed on Bloomberg. Apparently, a clinical trial sponsored by an OpRegen competitor has been significantly delayed, with a new anticipated primary completion date of their ongoing Phase I-B trial pushed out to December 31, 2027. While it's clearly not good for patients in need of treatment to experience extended timelines, this might also serve as a reminder that Lineage and our partners at Roche and Genentech remain furthest along in clinical development in this important and innovative field of RPE cell transplantation. Approvals for novel modalities can take longer than we'd all like, but we remain hopeful that OpRegen, which has previously demonstrated retinal restoration and improved visual acuity scores, will ultimately reach the market for the benefit of patients around the world.

Brian CulleyCEO

Moving next to AlloSCOPE, our proprietary manufacturing platform, I want to highlight that we recently announced the issuance of a patent underlying an application of the AlloSCOPE platform that we call 5D. 5D is a term we use to describe certain methods we employ to try and capture the positive features of 2D adherent cell manufacturing when performed in a 3D culture environment. We are doing this to try and capture the high-volume advantages and lower production costs for cell therapies that are expected to have high cell dose requirements, such as an islet cell therapy for the treatment of type 1 diabetes, which is expected to require hundreds of millions of cells or even 1 billion cells per patient. 5D offers more than just greater scale, so we are using 5D methods for other programs in our pipeline.

Brian CulleyCEO

This patent, therefore, is fundamental to our business, and we are extremely happy to have a new proprietary position for our platform with an expected patent expiration date into 2043. Speaking of islet cells, we believe the highest and best opportunity for our 5D technology may be for the production of islet cells because islet cells don't easily expand in culture. Yet, as I said, the dose requirement for an islet cell therapy is likely to be extremely high. We believe a cost-effective cell therapy for T1D will need to start with a huge number of undifferentiated cells that, importantly, retain their capacity to scale and specifically their pluripotency and response to differentiation factors before you even start turning them into islet cells.

Brian CulleyCEO

Our engineering efforts with ILT1 to date have focused on producing cells with these critical features and on a modality that can support both expansion and differentiation entirely in a closed culturing system with no inefficient 2D plating steps or vessel transfers. Because if this approach to generating large numbers of undifferentiated pluripotent stem cells is successful and applied to an islet cell differentiation protocol, it could potentially solve a major hurdle to production and commercialization of an islet cell therapy product for the treatment of type 1 diabetes. We have been successful this year in showing the scalability of our new 5D technology from 100 mL to 500 mL, and more recently to 3 liters.

Brian CulleyCEO

With those achievements behind us, we more recently shifted our efforts to showing that our 5D cells could actually differentiate into endodermal precursors, which is the first and necessary step for all islet differentiation protocols. I'm pleased to share today, for the first time, that our R&D team was able to differentiate pluripotent stem cells into islet cell precursors in a 5D system, and that those precursors exhibited the desired attributes when compared head-to-head against islet cell precursors made on a 2D system. Importantly, because these precursors are a common cell type to all islet differentiation protocols, this work opens multiple options to continue development, either independently or in an alliance with specialized parties. I will just note that regarding potential alliances, we are not interested in becoming a contract manufacturer, so I would anticipate that any such alliance would reflect the value of our enabling technology.

Brian CulleyCEO

I'm both pleased and impressed with how quickly this work has proceeded, and because we believe our 5D approach provides a differentiated solution to a major challenge facing the cell therapy industry, which is enabling commercially scalable, consistent, and cost-effective manufacturing of pluripotent cell-derived therapies, I will continue to keep you informed of our progress. In parallel to ILT1, we also have been deploying the 5D platform to produce corneal endothelial cells, so I'll discuss that program next. I am sometimes asked when we will have data from the COR1 program for the treatment of corneal dystrophies, so I just want to start by reminding everyone that the COR1 program is barely a year old. We disclosed it less than eight months ago, and it's already moved into preclinical animal testing, so we are moving very quickly, and we hope to continue to go quickly.

Brian CulleyCEO

As I just mentioned, we used our AlloSCOPE platform with the 5D technology and successfully achieved seamless precursor expansion and differentiation in a 3D bioreactor to produce corneal endothelial cells, which together with our proprietary thaw and inject formulation, meet our internal criteria for continued development. Knowing that our audience is eager to know how our cells perform in the established translational models, we then advanced those cells promptly into preclinical testing. We expect to have initial preclinical data internally by year-end and to share that data publicly in the first quarter of 2027. That is something we can all look forward to from the COR1 program. The other internally developed program that we successfully moved from product concept into preclinical testing in less than a year is ReSonance, our auditory neuronal cell therapy for the treatment of hearing loss.

Brian CulleyCEO

After producing these cells and generating some initial in vitro data with our academic collaborators at the University of Michigan, we entered in August 2025 into a $12 million research collaboration funded by William Demant Invest, WDI. WDI continues to fund preclinical development of this program, and at our recent joint steering committee meeting, we jointly decided to advance the collaboration into a second year. We also already scheduled our first regulatory interaction for ReSonance, a scientific advice meeting with the Danish Medicines Agency, which is scheduled for December.

Brian CulleyCEO

I want to pause here to highlight that we have shown not only for ourselves, but also for external partners, that we have moved to completely new and internally developed product candidates quickly and successfully through the early stages of manufacturing and development, and we've done this with capital investments that we invite to be compared with our cell therapy peers. We know innovation in cell therapy can be a long journey, so we strive to extract a return from each of our invested R&D dollars. We believe we have developed a track record to support our commitment to fiscal discipline, something we believe is prudent in good markets and essential in bad ones.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day